LDS/Medical Tests/Candida Species, PCR

Candida Species, PCR

Yeast infections due to Candida sp. (also known as candidiasis) are relatively common in the vagina (‘yeast infection’), the oropahrynx (thrush) and other moist areas of the body. Candida may also rarely infect the respiratory tract, GI tract or urinary tract in otherwise healthy individuals. Invasive candidiasis is a serious infection that can affect the blood, heart, brain, eyes, bones, and other parts of the body.

While C. albicans is normally present in skin, mouth, vagina, and intestine, it can flourish when changes occur in the microbial population. Also of note, while being an endogenous inhabitant of the mucocutaneous regions, and the alimentary tract, it can easily become an opportunistic pathogen in immunocompromised patients. Infection is usually localized in forms of oral candidiasis, vulvovaginitis, etc.; however, it can become systemic in rare circumstances if the yeast enters the blood or internal organs such as those in immunocompromised patients (HIV and transplant patients). Candidiasis of the intestines has been shown to be associated with the use of antibiotics. When bacterial conditions that are normally found in this organ are disrupted, the yeast can overpopulate and cause disease.

Of the Candida infections in clinical practice, more than 90% are caused by Candida albicans. Most common treatment is by antifungal agents such as azoles and nazoles. C. albicans and other species are often susceptible to the nazoles group of antifungal agents. However, there is a shift toward the more nazole-tolerant species, such as C. glabrata, C. tropicalis, and C. krusei, possibly related to the increasing use of itraconazole and fluconazole, the antifungal drugs that are typically the first choice in treating candidiasis. Therefore, detection and speciation is relevant for selection and use of the correct antifungal agent. PCR detection of Candida albicans and Candida spp which uses nucleic acid sequence specific probes is most reliable diagnostic test with high sensitivity and specificity.

  • As an aid in diagnosing candidiasis (Candida infection)
  • Differential diagnosis of yeast infections in immunocompromised patients
  • Disease management and therapy treatment monitoring

Positive in:

  • Candidiasis
  • Immunocompromised patients infected with C. albicans
  • Other yeast infections

Not Detected (Negative)

Real-time PCR, Other molecular methods.

Blood, Plasma, Swab from lesions, Vaginal Swab, Swab from infected areas, body fluids, CSF.

Stability vary depends on the specimens

Stability (blood or plasma)

  • Ambient: 7 days
  • Refrigerated: 7-14 days
Candida antibodies by ELISA, Candida antibodies by latex agglutination (LA), Fungal culture, Blood culture.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Med Microbiol. 2008 Mar;57(Pt 3):296-303. [PMID: 18287291]
  • J Microbiol. 2005 Feb;43 Spec No:65-84. [PMID: 15765060]
  • Mycopathologia. 1992 Nov;120(2):65-72. [PMID: 1480209]
  • Diagn Microbiol Infect Dis. 1985 Sep;3(5):419-32. [PMID: 2411467]
  • Stevens, Christine Dorresteyn. Clinical Immunology & Serology A Laboratory Perspective 3rd edition. Philadelphia: F.A. Davis Company. 2010.